Cardialen is closing in on a $4 million equity round, after raising $2.5 million from 18 unnamed investors.
Minneapolis and St. Louis-based Cardialen is developing a low-energy implant for atrial fibrillation designed to control the fibrillation without damaging heart tissue, according to its website.
The technology uses series of lower-energy pulses rather than a single high-energy shock to effect the therapy, according to the website.
The company has offered its 18 investors equity in Cardialen for the $2.5 million, according to the filing.
At DeviceTalks Boston, Tyler Shultz will give attendees an inside look at Theranos and how he was able to sound the alarm after he realized the company was falling apart. Shultz will take attendees behind the story that everyone is talking about: the rise and fall of Elizabeth Holmes and her diagnostic company, Theranos.
Join Shultz and 1,000+ medical device professionals at the 8th annual DeviceTalks Boston.